Floatz logo

Hydroxyurea

Astrocytoma

Novartis PharmaceuticalsSmall moleculePhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

16 Active assets in the Astrocytoma cohort.

Asset / SponsorPhaseRating
Carboplatin
Oliver Jonas
Phase 2BB
Irinotecan
Julie Krystal
Phase 2BB
Dabrafenib
Novartis Pharmaceuticals
Phase 4BB
gsk1120212
Novartis Pharmaceuticals
Phase 4BB
(+)-VINCRISTINE
Novartis Pharmaceuticals
Phase 2BB

View all 40 →

Same molecule, other indications

Hydroxyurea is also rated in:

beta-thalassemia majorDormant
BBB
Indicative ·
77 / 100
View asset →
sickle cell diseaseDormant
BB
Indicative ·
71 / 100
View asset →
thalassemiaDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →